Hansen Medical Names Robert Cathcart Senior Vice President of Global Sales
MOUNTAIN VIEW, CA, Jan 16, 2013 (MARKETWIRE via COMTEX) --
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in
intravascular robotics, today announced that Robert (Bob) Cathcart
has joined the Company in the newly created position of Senior Vice
President, Global Sales. Mr. Cathcart will report directly to Bruce
Barclay, President and Chief Executive Officer. The creation of this
position will allow Hansen Medical to most efficiently execute its
global sales strategy.
Mr. Cathcart has nearly 30 years of increasingly senior sales
management experience in both domestic and international roles in the
medical technology industry with large and small companies. From 2001
to 2009, Mr. Cathcart worked at Datascope Corporation (acquired by
Maquet), where he served as the Division President and Vice President
of Sales in the Cardiac Assist Division, and later the President of
the Interventional Products Division. While leading the Datascope
Cardiac Assist Division, Mr. Cathcart led the successful
restructuring of the sales organization in 2002, managed a 70 person
sales and clinical team and developed a sales training department.
During his four year tenure as Division President of Datascope
Interventional Products, he helped to launch three new products and
drove expansion into Europe and Asia.
"Bob is a strategic leader with extensive commercial and senior
management experience in the medical technology industry --
specifically interventional cardiology -- and is a great fit for
Hansen Medical," said Bruce Barclay, President and CEO of Hansen
Medical. "He has demonstrated success in developing high-performing
national and international sales organizations, and delivering growth
across multiple product lines, including capital equipment and
interventional products. With Bob's global experience and leadership,
we will continue to advance our commercial strategy to demonstrate
the truly platform-changing capability of intravascular robotics with
our Sensei(TM) and Magellan(TM) Robotic Systems."
Prior to joining Hansen Medical, Mr. Cathcart served as the Chief
Commercial Officer of surgical medical device start-up, HyperBranch
Medical Technology, where he was responsible for all sales and
marketing in international markets, including Europe, South America
and Asia Pacific. Earlier, he served as the President and CEO of
FlowCo, Inc./3DT Holdings, a privately-held medical device company
focused on interventional cardiology. Mr. Cathcart has also led the
sales functions of Promedix Inc., Bard Access Systems and MedChem
Products. He began his career at Davis + Geck, where he served as a
sales representative, global training manager, regional manager, and
eventually area director of the endo-surgery division. He holds a
Bachelor of Arts degree from DePauw University.
"As Hansen Medical's commercial momentum continues to grow, I am
pleased to be joining the team at such a critical juncture in the
Company's development," said Mr. Cathcart. "I believe that Hansen
Medical's intravascular robotic technology offers the clinical and
economic value increasingly demanded by physicians and hospitals in
today's challenging healthcare environment."
About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain
View, California, is the global leader in intravascular robotics,
developing products and technology designed to enable the accurate
positioning, manipulation and control of catheters and catheter-based
technologies. The Company's Magellan(TM) Robotic System,
NorthStar(TM) Robotic Catheter and related accessories, which are
intended to facilitate navigation to anatomical targets in the
peripheral vasculature and subsequently provide a conduit for manual
placement of therapeutic devices, have undergone both CE marking and
510(k) clearance and are commercially available in the European
Union, and the U.S. In the European Union, the Company's Sensei(R) X
Robotic Catheter System and Artisan Control Catheter are cleared for
use during electrophysiology (EP) procedures, such as guiding
catheters in the treatment of atrial fibrillation (AF), and the
Lynx(R) Robotic Ablation Catheter is cleared for the treatment of AF.
This robotic catheter system is compatible with fluoroscopy,
ultrasound, 3D surface map and patient electrocardiogram data. In the
U.S. the Company's Sensei X Robotic Catheter System and Artisan
Control Catheter were cleared by the U.S. Food and Drug
Administration for manipulation and control of certain mapping
catheters in EP procedures. In the United States, the Sensei System
is not approved for use in guiding ablation procedures; this use
remains experimental. The U.S. product labeling therefore provides
that the safety and effectiveness of the Sensei X System and Artisan
Control Catheter for use with cardiac ablation catheters in the
treatment of cardiac arrhythmias, including AF, have not been
established. Additional information can be found at
This press release contains
forward-looking statements regarding, among other things, statements
relating to goals, plans, objectives, milestones and future events.
All statements, other than statements of historical fact, are
statements that could be deemed forward-looking statements, including
statements containing the words "plan," "expects," "potential,"
"believes," "goal," "estimate," "anticipates," and similar words.
These statements are based on the current estimates and assumptions
of our management as of the date of this press release and are
subject to risks, uncertainties, changes in circumstances and other
factors that may cause actual results to differ materially from the
information expressed or implied by forward-looking statements made
in this press release. Examples of such statements include statements
about the potential benefits of our technology and the value of our
intellectual property portfolio. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, among others: engineering,
regulatory, manufacturing, sales and customer service challenges in
developing new products and entering new markets; potential safety
and regulatory issues that could slow or suspend our sales; the
effect of credit, financial and economic conditions on capital
spending by our potential customers; the uncertain timelines for the
sales cycle for newly introduced products; the rate of adoption of
our systems and the rate of use of our catheters; the scope and
validity of intellectual property rights applicable to our products;
competition from other companies; our ability to recruit and retain
key personnel; our ability to maintain our remedial actions over
previously reported material weaknesses in internal controls over
financial reporting; our ability to manage expenses and cash flow,
and obtain additional financing; and other risks more fully described
in the "Risk Factors" section of our Quarterly Report on Form 10-Q
for the quarter ended September 30, 2012 filed with the SEC on
November 9, 2012 and the risks discussed in our other reports filed
with the SEC. Given these uncertainties, you should not place undue
reliance on the forward-looking statements in this press release. We
undertake no obligation to revise or update information herein to
reflect events or circumstances in the future, even if new
information becomes available.
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan and
NorthStar are trademarks of Hansen Medical, Inc. in the United States
and other countries.
Peter J. Mariani
Chief Financial Officer
Hansen Medical, Inc.
FTI Consulting, Inc.
SOURCE: Hansen Medical, Inc.
[ Back To greentechnologyworld.com's Homepage ]